Nxstage Medical, Inc. (NXTM): Robert S. Brown, President, NxStage Kidney Care of Nxstage Medical, Inc. sold 10,825 shares on Aug 17, 2015. The Insider selling transaction was disclosed on Aug 18, 2015 to the Securities and Exchange Commission. The shares were sold at \$18.30 per share for a total value of \$198,097.50.

Currently the company Insiders own 2.3% of Nxstage Medical, Inc. Company shares. In the past six months, there is a change of -6.42% in the total insider ownership. Institutional Investors own 94.4% of Company shares. During last 3 month period, -1.93% of total institutional ownership has changed in the company shares. On a different note, The Company has disclosed insider buying and selling activities to the Securities Exchange, According to the information disclosed by the Securities and Exchange Commission in a Form 4 filing, the (President) of Nxstage Medical, Inc., Turk Joseph E Jr had sold 3,252 shares worth of \$57,690 in a transaction dated August 12, 2015. In this transaction, 3,252 shares were sold at \$17.74 per share. Shares of NxStage Medical, Inc. (NASDAQ:NXTM) rose by 1.56% in the past week and 28.57% for the last 4 weeks. In the past week, the shares have outperformed the S&P 500 by 0.88% and the outperformance increases to 30.73% for the last 4 weeks. Nxstage Medical, Inc. is up 9.27% in the last 3-month period. Year-to-Date the stock performance stands at 1.9%. The company shares have rallied 37.93% in the past 52 Weeks. On April 27, 2015 The shares registered one year high of \$19.63 and one year low was seen on September 16, 2014 at \$11.5. The 50-day moving average is \$14.92 and the 200 day moving average is recorded at \$16.69. S&P 500 has rallied 6.56% during the last 52-weeks. NxStage Medical, Inc. (NASDAQ:NXTM) : On Friday heightened volatility was witnessed in NxStage Medical, Inc. (NASDAQ:NXTM) which led to swings in the share price. The shares opened for trading at \$18.14 and hit \$18.4099 on the upside, eventually ending the session at \$18.27, with a gain of 0.27% or 0.05 points. The heightened volatility saw the trading volume jump to 335,709 shares. The 52-week high of the share price is \$19.63 and the company has a market cap of \$1,159 million. The 52-week low of the share price is at \$11.5 . NxStage Medical, Inc. (NxStage) is a medical device company that develops, manufactures and markets products for the treatment of kidney failure, fluid overload and related blood treatments and procedures. The Companys primary product is the NxStage System One (System One). It also sells needles and blood tubing sets primarily to dialysis clinics for the treatment of end-stage renal disease (ESRD). It operates in two segments: System One and In-Center. It distributes its products in three markets: home, critical care and in-center. In the System One segment it derives its revenues from the sale and rental of the System One and PureFlow SL equipment, and the sale of disposable products in the home and critical care markets. In the In-Center segment, it derives its revenues from the sale of blood tubing sets and needles for hemodialysis primarily for the treatment of ESRD patients at dialysis centers and needles for apheresis, which is referred to as the in-center market.
